Management of heavy uterine bleeding

Reading File

Finding Sources

Searching PubMed

"heavy menstrual bleeding" AND management

Finding Sources

Reading File

I now have comprehensive content. Let me compile the full answer.

Management of Heavy Uterine Bleeding (HUB)

Heavy uterine bleeding (HUB), also called heavy menstrual bleeding (HMB) or formerly menorrhagia, is defined as menstrual blood loss that interferes with a woman's physical, emotional, social, or quality-of-life. It is one of the most common gynecologic complaints.

1. Initial Assessment

Before treating, identify the underlying cause using the PALM-COEIN classification (structural vs. non-structural):

Structural (PALM): Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia
Non-structural (COEIN): Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified

Key evaluation steps:

CBC, coagulation studies (PT, aPTT), pregnancy test, thyroid function
Pelvic ultrasound (first-line imaging)
Endometrial biopsy for women >45 years or with risk factors (obesity, nulliparity, anovulation history, tamoxifen use, family history of endometrial/colon cancer)
Screen for bleeding disorders — especially in adolescents with HMB since menarche (von Willebrand disease accounts for up to 20% of acute uterine bleeding in adolescents)

When to suspect a bleeding disorder (Table 9-9, Berek & Novak):

HMB since menarche
Family history of bleeding disorder
Epistaxis, bruising >2 cm without injury, prolonged post-dental bleeding
Postpartum hemorrhage, especially delayed >24 hrs

2. Acute / Emergency Management (Hemodynamically Unstable)

(Tintinalli's Emergency Medicine, Table 96-4)

Agent	Dose	Notes
Conjugated equine estrogen (IV)	25 mg IV q4–6h until bleeding stops	Emergency GYN consult; give antiemetics. Contraindicated in VTE, thrombophilia, malignancy
Tranexamic acid (IV)	1.0–1.3 g IV	Can transition to PO 3×/day; effective within ~3 h. Contraindicated in VTE/thrombophilia
Fluid and blood resuscitation	As needed	Identify and treat coagulopathies; exclude pregnancy, foreign body, laceration

3. Medical Management (Hemodynamically Stable / Outpatient)

Non-hormonal

Agent	Dose	Mechanism
Tranexamic acid (FDA-approved for HMB)	1.3 g PO 3×/day for 3–5 days during menses	Antifibrinolytic; reduces blood loss ~30–50%. Effective for both idiopathic HMB and fibroid-related bleeding
NSAIDs (mefenamic acid, ibuprofen, naproxen)	Mefenamic acid 500 mg TID; ibuprofen 400 mg q6h; naproxen 500 mg BID for 4–5 days	Prostaglandin inhibition; reduces blood loss vs. placebo. Less effective in fibroid-related HMB

Hormonal

Agent	Regimen	Notes
Combined OCP (monophasic, ≤35 µg EE)	TID ×7 days (acute); then OD for maintenance	Bleeding stops in ~3 days. Contraindicated: smokers >35 yrs, HTN, VTE, liver disease, breast cancer
Progestin-only (medroxyprogesterone acetate)	20 mg PO TID ×7 days or OD ×10 days	For patients with contraindications to estrogen; more effective in older/perimenopausal women
Levonorgestrel IUS (Mirena)	In-office insertion	~50% amenorrhea at 1 year; highly effective for anovulatory and fibroid-related HMB
Depot medroxyprogesterone (DMPA)	150 mg IM q3 months	~50% amenorrhea at 1 year; monitor bone density with long-term use
GnRH agonists ± add-back therapy	Monthly injection ×6 months	Reduces fibroid volume 30–35%; used for preoperative downsizing. 95% experience side effects (hot flushes 78%, vaginal dryness 32%). Uterus returns to pretreatment size 4–6 months after stopping
GnRH antagonists (elagolix + low-dose add-back)	Oral daily	Newer option, phase III-approved for HMB from uterine fibroids/endometriosis

4. Special Clinical Scenarios

Anovulatory Bleeding

Mild (adequate Hgb, minimal disruption): menstrual charting, iron supplementation, close follow-up
Moderate–severe: combined OCP or cyclic progestins; LNG-IUS for long-term control
First-line in reproductive age: combined hormonal contraceptives or progestins (Berek & Novak, p. 410)

Fibroid-Related HMB

Watchful waiting acceptable if mildly symptomatic (77% stable at 1 year)
Medical: tranexamic acid, GnRH agonists (preoperative use), LNG-IUS
NSAIDs are not effective for fibroid-related HMB specifically

Coagulopathy (e.g., von Willebrand disease)

Avoid NSAIDs
Hormonal agents increase factor VIII and vWF levels
Desmopressin (DDAVP) stimulates endogenous release of factor VIII/vWF
Tranexamic acid and recombinant vWF as adjuncts
Multidisciplinary approach (hematology + gynecology)

Anticoagulated Patients

Combined contraceptives and tranexamic acid are contraindicated
Progestin-only with caution and GYN consultation
Weigh risks/benefits of anticoagulation reversal

PCOS

Low-dose OCP or progestins for cycle regulation and bleeding control

Perimenopausal Bleeding

10% risk of malignancy — prompt endometrial biopsy for all women >45
GnRH agonists or watchful waiting if approaching menopause

5. Surgical Management

Indicated when medical management fails or is contraindicated:

Procedure	Indication
Dilation & curettage (D&C)	Acute control; diagnostic
Hysteroscopy ± directed biopsy	Structural causes (polyps, submucosal fibroids)
Endometrial ablation	Completed childbearing; definitive for dysfunctional uterine bleeding
Myomectomy (hysteroscopic or laparoscopic)	Fibroid-related HMB; fertility preservation. 25–30% recurrence
Uterine artery embolization (UAE)	Fibroids; effective in reducing fibroid volume and symptoms
Hysterectomy	Last resort; life-threatening bleeding unresponsive to all other measures

Stable patients can be discharged with prompt outpatient follow-up after achieving initial hemostasis. (Tintinalli's, p. 653)

6. Key Prescribing Precautions

Contraindications to estrogen: active VTE, thrombophilia, vascular disease, malignancy, liver disease, smokers >35
Tranexamic acid contraindications: active VTE, thrombophilia
DMPA & GnRH agonists: monitor bone mineral density with long-term use
Always provide antiemetics when using high-dose estrogen

Sources:

Berek & Novak's Gynecology, pp. 409–414, 515
Tintinalli's Emergency Medicine, pp. 650–653 (Table 96-4)
Katzung's Basic and Clinical Pharmacology, 16th ed., p. 288

Recent evidence note: A 2025 systematic review (PMID 39617186) found coagulopathies (vWD, platelet disorders) are significantly under-recognized as a cause of HMB across both adolescents and adults — reinforcing the importance of screening. A 2025 Cochrane review (PMID 40183418) updated evidence on preoperative medical therapy for fibroids.

Endometriosis

Finding Sources

Searching PubMed

"endometriosis"[MeSH Terms] AND management

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive, detailed content from Robbins (pathology), Berek & Novak's Gynecology (management), and Goldman-Cecil Medicine (clinical features and treatment). Let me now compile the full comprehensive answer.

Endometriosis

Definition

Endometriosis is the presence of endometrial glands and stroma at sites outside the uterus. It affects approximately 10% of women of reproductive age and nearly 50% of women with infertility. (Robbins & Kumar Basic Pathology)

Classification / Types

There are three recognized types:

Superficial peritoneal endometriosis — flat implants on peritoneal surfaces
Ovarian endometriosis (endometriomas / "chocolate cysts") — ovarian cysts 3–5 cm filled with degenerated blood
Deep infiltrating endometriosis (DIE) — lesions penetrating >5 mm below peritoneal surface; highest risk of malignant transformation

Common sites: ovaries, pouch of Douglas, uterosacral ligaments, fallopian tubes, bladder, rectum, peritoneum. Distant sites (lung, umbilicus, surgical scars) occur via lymphovascular spread.

Pathogenesis

Several complementary theories exist (Robbins, p. 689):

Theory	Mechanism
Regurgitation (Sampson's)	Retrograde menstruation → implantation of endometrial cells at ectopic pelvic sites (most accepted)
Benign metastasis	Lymphovascular spread to distant sites (lung, bone, brain)
Coelomic metaplasia	Differentiation of peritoneal mesothelium into endometrial tissue (explains distant/non-pelvic lesions)
Stem/progenitor cell	Bone marrow–derived stem cells differentiate into ectopic endometrium

Molecular sustaining factors:

Endometriotic implants produce ↑ prostaglandin E2, VEGF, and matrix metalloproteinases (MMPs)
Recruited macrophages amplify local inflammation
High aromatase expression → increased local estrogen production → self-sustaining growth cycle
Disease is estrogen-dependent and progesterone-resistant

Pathogenesis of endometriosis — interplay between implant-derived factors and macrophages. COX-2/PGE2 cycle sustains implant growth. (Robbins & Kumar, Fig. 17.9)

Morphology

Grossly, lesions appear as red-brown nodules (1–2 cm) on serosal surfaces due to cyclic hemorrhage. Organizing hemorrhage → fibrous adhesions → distortion of pelvic anatomy. Ovarian endometriomas contain dark brown, tarry fluid ("chocolate cysts").

Ovarian endometriosis — sectioned ovary showing multiple endometriotic cysts with degenerated blood. (Robbins, Fig. 17.10)

Histology: requires both endometrial glands AND stroma at ectopic site for definitive diagnosis.

Clinical Features

Classic triad:

Dysmenorrhea (severe, often progressive) — most common presenting symptom
Dyspareunia (deep)
Chronic pelvic pain

Additional features:

Infertility — 30–40% present with infertility as primary complaint
Menstrual irregularities, heavy periods
Dyschezia (painful defecation) — DIE involving rectum
Dysuria — bladder involvement
Cyclical haematuria, haemoptysis (rare thoracic endometriosis)

Natural history: Progressive in 30–60% within 1 year without treatment. Deterioration seen in 47%, improvement in 30%, resolution in 23% over 6 months in observational studies. (Berek & Novak, p. 651)

Staging (rASRM / ESHRE)

The revised American Society for Reproductive Medicine (rASRM) classification scores implants, adhesions, and endometrioma involvement:

Stage	Score	Description
I	1–5	Minimal
II	6–15	Mild
III	16–40	Moderate
IV	>40	Severe

Limitation: rASRM staging correlates poorly with pain severity or fertility prognosis. The Endometriosis Fertility Index (EFI) better predicts pregnancy rates post-surgery.

Diagnosis

Definitive diagnosis: laparoscopy with histological confirmation (biopsy showing glands + stroma)
Pelvic ultrasound: first-line imaging; identifies endometriomas ("ground-glass" appearance); limited for peritoneal and DIE lesions
MRI pelvis: gold standard for mapping DIE; used in surgical planning for complex disease
CA-125: may be elevated but non-specific; not used for diagnosis alone
No reliable non-invasive biomarker exists to date

Empirical treatment (without laparoscopy) is acceptable in adolescents and women with classic symptoms when imaging is unremarkable — NSAIDS + hormonal therapy trial.

Management

Treatment must be individualized based on: symptom severity, desire for fertility, age, extent of disease, and patient preferences. Endometriosis is a chronic, relapsing condition — recurrence is common after both medical and surgical treatment. (Berek & Novak, p. 655)

1. Analgesics (First-Line for Pain)

NSAIDs (ibuprofen 400–800 mg q4–6h; naproxen 500 mg BD; mefenamic acid 500 mg TDS) — inhibit prostaglandin synthesis; effective for dysmenorrhea
Start at onset of menses or cramping, continue up to 3 days
COX-2 inhibitors — effective; reduce risk of GI side effects
Opioids: avoid long-term; consider pain clinic referral for refractory chronic pelvic pain

2. Hormonal Medical Therapy

All hormonal therapies aim to suppress ovulation and reduce estrogen stimulation of implants. None are curative — symptoms typically recur after stopping.

Agent	Dose	Notes
Combined OCP (continuous or cyclic)	Standard dose OCP continuously	First-line; reduces dysmenorrhea; prevents endometrioma recurrence post-surgery (94% free at 36 months vs. 51% without OCP). Cyclic and continuous use both effective
Progestins — norethindrone acetate	5 mg/day orally	Effective for pain; fewer estrogen-related side effects; well-tolerated long-term
DMPA (depot MPA)	150 mg IM q3 months	Induces amenorrhea; effective for pain; monitor bone density
LNG-IUS (Mirena)	In-office insertion	Reduces dysmenorrhea and chronic pelvic pain; local delivery; fertility returns after removal
GnRH agonists (leuprorelin, triptorelin, nafarelin)	Leuprorelin 3.75 mg SC monthly or 11.25 mg q3 months	Creates medical "pseudomenopause"; highly effective. Side effects: hot flushes (78%), vaginal dryness, bone loss. Add-back therapy (low-dose estrogen ± progestin) recommended for use >6 months
GnRH antagonists (elagolix, relugolix)	Elagolix 150 mg orally daily (up to 24 months)	Oral; rapid onset; dose-dependent hypoestrogenism. Elagolix FDA-approved for endometriosis pain
Danazol	200–400 mg BD–TDS	Androgenic/antigonadotropic; effective but poorly tolerated (acne, hirsutism, hepatotoxicity); largely replaced by GnRH agents
Aromatase inhibitors (letrozole, anastrozole) ± add-back	Letrozole 2.5 mg/day	For refractory/recurrent disease; targets aromatase overexpression in implants; always combine with OCP or GnRH agonist to prevent ovarian stimulation

Post-surgical hormonal suppression:

Routine post-op GnRH agonist does not significantly reduce pain recurrence at 12 months vs. placebo alone
Post-op OCP use significantly reduces endometrioma recurrence (36-month recurrence-free rate: 94% OCP users vs. 51% non-users) — recommended (Berek & Novak, p. 661–662)

3. Surgical Treatment

Indications:

Failure of medical therapy
Desire for fertility (infertility as primary complaint)
Endometrioma >3 cm
Severe/deep infiltrating endometriosis
Diagnostic uncertainty

Laparoscopy is the gold standard (preferred over laparotomy — reduces adhesion formation):

Procedure	Details
Fulguration/ablation of implants	Laser or diathermy; effective for superficial disease
Excision (laparoscopic)	Complete excision preferred over ablation for deep/DIE lesions; better long-term pain outcomes
Cystectomy (endometrioma)	Excision of cyst wall preferred over drainage alone — lower recurrence
Adhesiolysis	Restores pelvic anatomy; barrier agents (oxidised cellulose) may reduce re-adhesion
Presacral neurectomy (PSN)	Effective additional procedure for midline pain; requires high surgical skill; LUNA adds no benefit

Laparoscopic surgery vs. diagnostic laparoscopy alone: OR 5.72 (95% CI 3.09–10.60) at 6 months; OR 7.72 (95% CI 2.97–20.06) at 12 months favouring surgical treatment. (Berek & Novak, p. 660)

Definitive surgery (hysterectomy ± bilateral salpingo-oophorectomy):

Reserved for women who have completed childbearing with severe, refractory disease
BSO reduces recurrence risk but causes surgical menopause — HRT decisions require individualisation

4. Management of Infertility

Mild–moderate endometriosis: laparoscopic ablation/excision improves spontaneous pregnancy rates (NNT ~12)
Severe/DIE: surgical resection before ART improves IVF outcomes
Hormonal therapy does not improve fertility — suppress ovulation and fertility during treatment
IVF/ICSI: recommended for infertility with advanced disease or failed conservative surgery
Use EFI (Endometriosis Fertility Index) to counsel patients on expected pregnancy rates post-surgery

5. Special Populations

Adolescents:

Empirical treatment (NSAIDs + OCP) first
Laparoscopy if no response to 3–6 months of medical therapy (endometriosis found in up to 70% of adolescents with refractory pelvic pain)
Subtle atypical lesions (red, clear, white) are more common than classic black lesions in this age group

Perimenopausal women:

Symptoms usually improve after menopause (estrogen withdrawal)
HRT after surgical menopause: add progestin to protect against stimulation of residual implants

Extragenital endometriosis:

Thoracic (catamenial pneumothorax, haemoptysis): hormonal suppression ± surgical pleurodesis
Umbilical/scar endometriosis: excision
Bowel/bladder DIE: multidisciplinary surgical approach (colorectal + gynecology)

Malignant Transformation

Endometriosis-associated ovarian cancer (primarily clear cell carcinoma and endometrioid adenocarcinoma) occurs in ~1% of cases
Risk mainly confined to deep infiltrating and ovarian endometriosis
Surveillance: ultrasound monitoring for endometriomas; rising CA-125 warrants reassessment

Summary Algorithm

Suspected endometriosis (dysmenorrhea ± pelvic pain ± infertility)
          ↓
First-line: NSAIDs + combined OCP (3–6 months)
          ↓ if inadequate response
Add or switch: GnRH agonist + add-back / GnRH antagonist / progestins
          ↓ if inadequate response or infertility/diagnostic uncertainty
Laparoscopy: confirm diagnosis + surgical treatment (excision preferred)
          ↓ post-surgery
Continuous OCP or LNG-IUS (reduces recurrence)
          ↓ if severe refractory disease + childbearing complete
Definitive surgery (hysterectomy ± BSO) + individualised HRT

Sources:

Robbins & Kumar Basic Pathology, pp. 688–689 (pathogenesis, morphology)
Berek & Novak's Gynecology, pp. 651–665 (management, surgical outcomes, post-op hormonal therapy)
Goldman-Cecil Medicine, pp. 2554–2555 (clinical features, treatment options)

Recent evidence notes:

A 2026 systematic review (PMID 40705433) found physiotherapy significantly reduces endometriosis-associated pelvic pain — consider as adjunct.
A 2025 meta-analysis (PMID 39946383) supports physical activity/exercise as effective for reducing pain and improving quality of life in endometriosis.
A 2025 meta-analysis (PMID 39358652) on dietary interventions (anti-inflammatory diet, omega-3) showed modest benefit for pain reduction.

This is a shared conversation. Sign in to Orris to start your own chat.